Graybug Vision (GRAY) Competitors $2.37 -0.12 (-4.64%) As of 08/13/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock GRAY vs. NNVC, TAOX, IBIO, OBSV, AEON, MTNB, AEZS, NRBO, VAXX, and SPRBShould you be buying Graybug Vision stock or one of its competitors? The main competitors of Graybug Vision include NanoViricides (NNVC), Synaptogenix (TAOX), iBio (IBIO), ObsEva (OBSV), AEON Biopharma (AEON), Matinas Biopharma (MTNB), Aeterna Zentaris (AEZS), NeuroBo Pharmaceuticals (NRBO), Vaxxinity (VAXX), and Spruce Biosciences (SPRB). Graybug Vision vs. Its Competitors NanoViricides Synaptogenix iBio ObsEva AEON Biopharma Matinas Biopharma Aeterna Zentaris NeuroBo Pharmaceuticals Vaxxinity Spruce Biosciences Graybug Vision (NASDAQ:GRAY) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations. Do insiders & institutionals have more ownership in GRAY or NNVC? 49.9% of Graybug Vision shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 7.9% of Graybug Vision shares are owned by company insiders. Comparatively, 4.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer GRAY or NNVC? In the previous week, Graybug Vision had 1 more articles in the media than NanoViricides. MarketBeat recorded 1 mentions for Graybug Vision and 0 mentions for NanoViricides. Graybug Vision's average media sentiment score of 0.00 equaled NanoViricides'average media sentiment score. Company Overall Sentiment Graybug Vision Neutral NanoViricides Neutral Is GRAY or NNVC more profitable? Graybug Vision's return on equity of -77.61% beat NanoViricides' return on equity.Company Net Margins Return on Equity Return on Assets Graybug VisionN/A -77.61% -71.34% NanoViricides N/A -87.90%-78.69% Which has more risk and volatility, GRAY or NNVC? Graybug Vision has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Which has stronger earnings & valuation, GRAY or NNVC? NanoViricides is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGraybug VisionN/AN/A-$35.60M-$24.23-0.10NanoViricidesN/AN/A-$8.29M-$0.70-2.10 SummaryGraybug Vision beats NanoViricides on 7 of the 9 factors compared between the two stocks. Get Graybug Vision News Delivered to You Automatically Sign up to receive the latest news and ratings for GRAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRAY vs. The Competition Export to ExcelMetricGraybug VisionPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.72M$791.77M$5.61B$9.84BDividend YieldN/A4.84%4.61%4.07%P/E Ratio-1.371.1830.2825.74Price / SalesN/A26.06460.47115.79Price / CashN/A19.5638.2159.48Price / Book1.426.588.856.15Net Income-$35.60M-$4.98M$3.25B$265.06M7 Day Performance-21.17%1.86%3.72%2.60%1 Month Performance1.94%0.45%5.86%2.83%1 Year Performance-42.32%16.14%30.34%25.58% Graybug Vision Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRAYGraybug VisionN/A$2.37-4.6%N/A-47.8%$3.72MN/A-1.3727News CoverageGap UpHigh Trading VolumeNNVCNanoViricides0.3107 of 5 stars$1.54flatN/A-23.0%$24.75MN/A-2.1420TAOXSynaptogenixN/A$8.34+12.9%N/AN/A$10.27MN/A-0.834Positive NewsGap DownIBIOiBio1.1988 of 5 stars$0.57-2.3%$5.00+772.4%-63.4%$9.47M$375K0.00100Gap UpOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050Gap DownAEONAEON Biopharma3.4375 of 5 stars$0.69+5.0%$360.00+52,134.5%-98.9%$7.79MN/A3.835Gap DownMTNBMatinas Biopharma1.53 of 5 stars$1.48-7.5%N/AN/A$7.53MN/A-0.3130Short Interest ↓Gap UpAEZSAeterna ZentarisN/A$3.58-0.4%N/A-45.4%$6.42M$2.37M-0.2420NRBONeuroBo PharmaceuticalsN/A$0.64+1.3%N/A-84.0%$5.50MN/A0.0010Gap UpVAXXVaxxinityN/A$0.04+42,900.0%N/A-99.5%$5.45MN/A-0.1090Gap UpSPRBSpruce Biosciences2.0448 of 5 stars$9.15-8.4%$131.25+1,334.4%-71.3%$5.14M$4.91M-9.7320News CoverageShort Interest ↑Gap Down Related Companies and Tools Related Companies NNVC Competitors TAOX Competitors IBIO Competitors OBSV Competitors AEON Competitors MTNB Competitors AEZS Competitors NRBO Competitors VAXX Competitors SPRB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRAY) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Graybug Vision, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Graybug Vision With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access